Piracetam
Piracetam is a nootropic substance of the racetam class and a cyclic derivative of the neurotransmitter GABA.12 First synthesized in 1964 by Corneliu E. Giurgea at the Belgian pharmaceutical company UCB,3 it became the first nootropic drug to modulate cognitive function without causing sedation or stimulation.23 Piracetam is the earliest and least potent racetam, requiring doses approximately 100 times higher than newer derivatives like noopept. It is prescribed in some countries for myoclonus45 and used off-label for cognitive enhancement.6
Contents
Dosage & Duration
Dosage
Duration
Subjective Effects
Piracetam is described as a nootropic that influences cognitive function without acting as a sedative or a stimulant, and it was characterized on introduction as the first such compound to modulate cognition without producing either effect. Reported benefits center on memory, learning, and general cognition, particularly in states of cognitive decline. Some users report noticeable effects on the first day at around 800 mg, with the same dose feeling less pronounced on subsequent days. Adverse experiences, when they occur, tend toward anxiety, irritability, restlessness, and headache rather than perceptual change.
Physical
Physical effects are largely absent by design, with neither sedation nor psychostimulation reported as characteristic; occasional reports include somnolence, weakness, weight gain, headache, tremor, and hyperkinesia. Increased libido and hypersexuality are also occasionally reported.
Bodily
Uncomfortable
Cognitive
The headspace is reported as improved recall, spatial memory, learning capacity, and attention rather than an altered state of consciousness. Anxiety, irritability, agitation, nervousness, and occasional depressed mood are reported as adverse effects, though some sources suggest the overall effect on lowering depression and anxiety may exceed the effect on memory.
Emotional
Enhancements
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Piracetam's mechanism of action is not fully understood, though it influences both neuronal and vascular functions without acting as a sedative or stimulant.1 The drug is a positive allosteric modulator of the AMPA receptor, although this action is weak and may not fully account for its clinical effects.7 Piracetam is also an inhibitor of N-type calcium channels, with an IC50 of approximately 3 μM in rat neurons, well below the central nervous system concentrations achieved at typical doses.8 Rather than binding with high affinity to specific receptors, piracetam appears to modulate neurotransmission by interacting with polar heads in phospholipid membranes, stabilizing membrane fluidity and potentially increasing the density and function of postsynaptic receptors including NMDA receptors.9 Through this membrane-stabilizing action, piracetam enhances cholinergic neurotransmission via muscarinic acetylcholine receptors and may influence glutamatergic, serotonergic, and noradrenergic systems.1 GABA brain metabolism and GABA receptors are not affected by piracetam despite its structural similarity to GABA.10 At the vascular level, piracetam increases erythrocyte deformability, reduces platelet aggregation, diminishes erythrocyte adhesion to vascular endothelium, and reduces capillary vasospasm, collectively improving microcirculation including cerebral blood flow.111
Pharmacokinetics
Piracetam is rapidly and extensively absorbed following oral administration, with absolute bioavailability close to 100%.11 Peak plasma concentration is reached within 1 hour in fasted subjects, though food intake may delay this to 1.5 hours and reduce peak concentration by approximately 17%.11 The drug distributes to all tissues except adipose tissue with a volume of distribution of approximately 0.6 L/kg, crosses the blood-brain barrier, and is not bound to plasma proteins.11 Piracetam undergoes negligible metabolism, with approximately 90% of the dose excreted unchanged in the urine.11 Steady state plasma concentrations are achieved within 3 days of dosing.11
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Racetam nootropics (aniracetam, pramiracetam, and related compounds)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowPiracetam can be considered non-addictive with a low potential for abuse. It does not appear to be capable of causing psychological dependence among users.
Physical
Extremely LowThere may be discontinuation symptoms if used for a prolonged period of time; tapering is recommended in these situations.
Toxicity
History & Culture
Discovery and Development
Piracetam was first synthesized sometime between the 1950s and 1964 by Corneliu E. Giurgea and his team at the Belgian pharmaceutical company UCB. There are reports of the compound being investigated for epilepsy treatment during the 1950s. Giurgea was struck by the substance's apparent ability to…
Legality
By Country
References
Source Pages
Citations
- (2005). Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Reviews, 11(2), 169–182. https://doi.org/10.1111/j.1527-3458.2005.tb00268.x1234
- Chen SY, Liu JW, Wang YH, Huang JY, Chen SC, Yang SF, & Wang PH. (2019). The Conditions Under Which Piracetam Is Used and the Factors That Can Improve National Institute of Health Stroke Scale Score in Ischemic Stroke Patients and the Importance of Previously Unnoticed Factors From a Hospital-Based Observational Study in Taiwan. Journal of Clinical Medicine, 8(1), 122. https://doi.org/10.3390/jcm801012212
- Yan H, Zhou M, Pan Z, Peng Y, Wang J, Li X, Xie Y, Liu Q, Huang C, Wang Q, & Liu G. (2026). Pharmacokinetics and Bioequivalence Evaluation of Piracetam Tablet: A Randomized, Single-Dose, Two-Period, Crossover Study in Healthy Chinese Participants Under Fasting and Fed Conditions. Drugs in R&D. https://doi.org/10.1007/s40268-026-00541-012
- Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salama M, Waegemans T, & Marsden CD. (1993). Effectiveness of piracetam in cortical myoclonus. Movement Disorders, 8(1), 63-68. https://pubmed.ncbi.nlm.nih.gov/8419809/1
- (n.d.). Nootropil 800 mg film-coated tablets - Summary of Product Characteristics (SmPC). electronic Medicines Compendium (emc). https://www.medicines.org.uk/emc/product/101129/smpc1
- (March 2020). Presence of Piracetam in Cognitive Enhancement Dietary Supplements. JAMA Internal Medicine, 180(3), 458–459. https://doi.org/10.1001/jamainternmed.2019.55071234
- (March 2010). Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. Journal of Medicinal Chemistry, 53(5), 2197–2203. https://doi.org/10.1021/jm901905j1
- (October 2012). A novel CaV2.2 channel inhibition by piracetam in peripheral and central neurons. Experimental Biology and Medicine, 237(10), 1209–1218. https://doi.org/10.1258/ebm.2012.0121281
- (March 1999). Piracetam: novelty in a unique mode of action. Pharmacopsychiatry, 32(Suppl 1), 2–9. https://doi.org/10.1055/s-2007-9792301
- (February 2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. https://doi.org/10.2165/11319230-000000000-000001
- UCB Pharma. (2013). Nootropil (piracetam) - Data Sheet. UCB Pharma. https://www.e-lactancia.org/media/papers/Piracetam-DS-UCB2013.pdf1234567
- (n.d.). Nootropil 1200 mg film-coated tablets - Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (emc). https://www.medicines.org.uk/emc/product/101131/smpc123456
- (May 1994). Piracetam and other structurally related nootropics. Brain Research. Brain Research Reviews, 19(2), 180–222. https://doi.org/10.1016/0165-0173(94)90011-6123
- Alzheimer's Drug Discovery Foundation. (2019). Piracetam - Cognitive Vitality Reports. Alzheimer's Drug Discovery Foundation (ADDF). https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Piracetam-Cognitive-Vitality-For-Researchers.pdf12
- (n.d.). 2.4 Piracetam — Scheduling Delegate's Interim Decisions, February 2016. Therapeutic Goods Administration (TGA). https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions-and-invitation-further-comment-accsacms-february-2016/24-piracetam1
- (n.d.). Drug Identification Number (DIN) — Fact Sheet. Health Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fact-sheets/drug-identification-number.html1
- (n.d.). Bringing medicines to Finland. Finnish Medicines Agency (Fimea). https://fimea.fi/en/for_public/travellers_medicines1
- (n.d.). Anlage 1 AMVV - Einzelnorm. https://www.gesetze-im-internet.de/amvv/anlage_1.html1
- (n.d.). Importing Medicines. Medsafe — New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/consumers/miet/importmedicines.asp1
- (n.d.). Classification Status of Racetams. Medsafe — New Zealand Medicines and Medical Devices Safety Authority. https://www.medsafe.govt.nz/profs/class/Agendas/agen53Racetams.pdf1
- (n.d.). NOOTROPIL Filmtabl 800 mg — Arzneimittel-Kompendium der Schweiz. compendium.ch (Swiss Drug Compendium). https://compendium.ch/product/12355-nootropil-filmtabl-800-mg1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Piracetam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.